Since this month, at least 8 pharmaceutical companies have obtained financing, and state-owned capital has frequently appeared as an investor.

Mirxes, an miRNA technology and cancer liquid biopsy enterprise, announced that it has reached a $40 million strategic financing with the Ruiqiao Credit Fund under CBridge Capital. Weimai, the largest full-course disease management service platform in China, announced that it has completed a RMB 200 million Series D financing. Since this month, at least 8 pharmaceutical enterprises (with headquarters in China or having a layout in China) have obtained financing. In addition to the aforementioned enterprises, MiaoShun Bio, ImmuneOnco, Libang Pharma, Puqi Pharma, and Onic MedTech have also received financing. In this wave of financing, state-owned capital frequently appears. Among these 8 enterprises, 6 companies have state-owned funds participating in the investment. (Yicai)